Acetylcholine in irritable bowel syndrome pathogenesis and the role of cholineblockers

Acetylcholine in irritable bowel syndrome pathogenesis and the role of cholineblockers

The aim of review. To demonstrate value of disorders of cholinergic innervation in pathogenesis of irritable bowel syndrome (IBS).Original positions. The important place in regulation of gastro-intestinal tract functions belongs not only to M-, but also to N-receptors localized in enteral plexus gan...

Full description

Saved in:

Bibliographic Details
Main Author:	Yu. O. Shulpekova
Format:	Article
Language:	Russian
Published:	Gastro LLC 2011-02-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	irritable bowel syndrome acetylcholine cholinoblockers hyoscine butylbromide
Online Access:	https://www.gastro-j.ru/jour/article/view/1365
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Issues of diagnostics and treatment of abdominal pain at irritable bowel syndrome at outpatient stage of the healthcare
by: Yu. A. Kucheryavy, et al.
Published: (2015-12-01)

The treatment of irritable bowel syndrome from the modern views on the disease pathogenesis
by: Ye. A. Poluektova, et al.
Published: (2013-03-01)

Role of nutritional factors at the irritable bowel syndrome
by: Yu. O. Shulpekova, et al.
Published: (2015-10-01)

Pathogenetic Substantiation of the Therapeutic Impact on Microbiota in Irritable Bowel Syndrome
by: Yu. O. Shulpekova, et al.
Published: (2019-09-01)

Combination of functional dyspepsia syndrome and irritable bowel syndrome
by: V. T. Ivashkin, et al.
Published: (2011-06-01)

Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia
by: V. T. Ivashkin, et al.
Published: (2022-01-01)

Irritable Bowel Syndrome in Terms of Changes in the Microbiota
by: Vladimir T. Ivashkin, et al.
Published: (2019-03-01)

Postinfectious Irritable Bowel Syndrome: Polemic and Open Issues
by: A. A. Sheptulin, et al.
Published: (2022-03-01)

Interrelation of irritable bowel syndrome and bacterial overgrowth: is there any?
by: Yu. A. Kucheryavy, et al.
Published: (2014-08-01)

Features of nervous system in children with irritable bowel syndrome
by: O. K. Botvin’yev, et al.
Published: (2011-12-01)

Use of Bismuth in Irritable Bowel Syndrome
by: T. A. Ilchishina
Published: (2021-10-01)

Irritable Bowel Syndrome Diagnosis: Should There Be Alertness to Cancer?
by: A. A. Sheptulin, et al.
Published: (2019-05-01)

Inflammatory Bowel Diseases and Irritable Bowel Syndrome: Overlap of Two Nosological Forms or Two Variants of the Same Disease?
by: A. A. Sheptulin, et al.
Published: (2019-12-01)

Pathogenic role of intestinal microflora changes in patients with irritable bowel syndrome and treatment options
by: Ye. A. Poluektova, et al.
Published: (2014-09-01)

Effect of biofeedback – therapy on clinical semiology, quality of life and sensorimotor function of anorectal area at irritable bowel syndrome with refractory constipation
by: O. V. Krapivnaya
Published: (2014-07-01)

Discussion of the problem of functional constipation and irritable bowel syndrome in the reports of the International Congress on Neurogastroenterology and Motility (Bologna, 2012)
by: A. A. Sheptulin, et al.
Published: (2013-03-01)

Irritable Bowel Syndrome Onset after New Coronavirus Infection COVID-19
by: I. Yu. Feklina, et al.
Published: (2022-03-01)

COVID-19 Pandemic and Irritable Bowel Syndrome — is there a Relationship?
by: V. A. Akhmedov
Published: (2022-08-01)

Fermented-milk bacteria: role in intestinal peristalsis regulation
by: Yu. O. Shulpekova
Published: (2010-06-01)

Esophageal lesions at irritable bowel syndrome
by: M. G. Mnatsakanyan, et al.
Published: (2015-10-01)

Combined alverine citrate and simeticonein preparation in the treatment of irritable bowel syndrome
by: Ye. A. Poluektova, et al.
Published: (2012-07-01)

Experience in the Treatment of Irritable Bowel Syndrome Developed after a New Coronavirus Infection (COVID-19)
by: R. G. Myazin
Published: (2022-05-01)

Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in Patients with Irritable Bowel Syndrome who Have Suffered COVID-19
by: A. V. Nalyotov, et al.
Published: (2022-09-01)

Irritable Bowel Syndrome: What Are the Reasons for Dissatisfaction with the Treatment of Patients and Doctors? (Based on the Experience of Medical Institutions of the Northwestern Federal District of Russia)
by: A. Yu. Baranovsky, et al.
Published: (2024-01-01)

Management of a Female Patient with Irritable Bowel Syndrome and Somatoform Disorder
by: E. A. Trush, et al.
Published: (2023-02-01)

Role of emotional disorders, personality features and disorders of intraceptive sensation in development of somatic symptoms at irritable bowel syndrome
by: Ye. A. Poluektova, et al.
Published: (2013-12-01)

Irritable bowel syndrome: pathophysiological and clinical issues
by: V. T. Ivashkin, et al.
Published: (2015-03-01)

Eating Habits, Anxiety and Depression in Patients with Irritable Bowel Syndrome: Clinical and Laboratory Comparisons
by: O. V. Gaus, et al.
Published: (2023-08-01)

Comparative efficacy of <i>Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus</i> composition and prucalopride in treatment of constipation variant of irritable bowel syndrome
by: V. T. Ivashkin, et al.
Published: (2015-07-01)

Single Nucleotide Polymorphisms, Associated with Increased Risk of Irritable Bowel Syndrome with Predominant Constipation: A Meta Analysis
by: E. A. Trush, et al.
Published: (2024-08-01)

Irritable Bowel and Bacterial Overgrowth Syndromes: a Bacterial Link Hypothesis of Functional Disease
by: K. V. Ivashkin, et al.
Published: (2021-04-01)

Comparative assessment of <i>Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus rhamnosus</i> and <i>Saccharomyces boulardii</i> efficacy at diarrheal variant of irritable bowel syndrome
by: V. T. Ivashkin, et al.
Published: (2015-05-01)

Effect of combined therapy by pinaverium bromide and itopride hydrochloride on clinical semiology and quality of life of patients with combination of constipation variant of irritable bowel syndrome and functional dyspepsia
by: O. V. Krapivnaya, et al.
Published: (2015-05-01)

Quality of Life and Level of Physical Activity In Students with and without Symptoms of Functional Dyspepsia and Irritable Bowel Syndrome Surveyed with Questionnaire “7×7” (7 Symptoms Per 7 Days)
by: T. V. Zhestkova
Published: (2020-07-01)

Discussion of irritable bowel syndrome issue and functional constipations in reports of the 21st United European Gastroenterological Week (Berlin, 2013)
by: A. A. Sheptulin, et al.
Published: (2014-09-01)

COVID-19 Pandemic and IBS. Results of the All-Russian Observational Non-interventional Program to Study the Effectiveness of the Drug Kolofort® in Real Clinical Practice in Patients with Irritable Bowel Syndrome After a New Coronavirus Infection (VESNA)
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

Dynamics of Somatic and Comorbid Mental Disorders (Distress, Anxiety, Somatisation and Depression) in Patients with Irritable Bowel Syndrome during Therapy with Alimemazine: Results of an Non-Interventional Observational Programme (“Terra”)
by: V. T. Ivashkin, et al.
Published: (2019-01-01)

Bowel diseases and constipation in practice of the obstetrician and gynecologist
by: I. V. Kuznetsova, et al.
Published: (2015-03-01)

Determination of Probiotics Prescription Indications in Patients with Irritable Bowel Syndrome (Materials of the Expert Council and Literature Review)
by: V. T. Ivashkin, et al.
Published: (2022-08-01)

The Role of Motility Impairment in the Pathogenesis of Functional Disorders of the Gastrointestinal Tract and Modern Possibilities for Their Treatment (Resolution of an Expert Council and Literature Review)
by: I. V. Maev, et al.
Published: (2020-01-01)